Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.

[1]  H. Kantarjian,et al.  Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. , 2015, The Lancet. Haematology.

[2]  Aaron N. Winn,et al.  Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Arias.  United States life tables, 2009. , 2014, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[4]  H. Kantarjian,et al.  Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. , 2013, Clinical lymphoma, myeloma & leukemia.

[5]  R. Paquette,et al.  Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY) , 2013 .

[6]  Joseph A Hill.  United States Life Tables , 2013 .

[7]  H. Brenner,et al.  Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century , 2013, Journal of Hematology & Oncology.

[8]  U. Olsson‐Strömberg,et al.  Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. , 2013, Blood.

[9]  Francisco Cervantes,et al.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.

[10]  D. Neuberg,et al.  Trends in all‐cause mortality among patients with chronic myeloid leukemia , 2013, Cancer.

[11]  R. Larson,et al.  Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. , 2013, Blood.

[12]  I. Flinn,et al.  Ponatinib in refractory Philadelphia chromosome-positive leukemias. , 2012, The New England journal of medicine.

[13]  J. Cortes,et al.  Understanding United States (US) Treatment Practices for the Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: A US Subgroup Analysis of the WORLD CML Registry. , 2012 .

[14]  E. Arias,et al.  United States life tables, 2008. , 2012, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[15]  T. Brümmendorf,et al.  Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Baccarani,et al.  Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). , 2012, Blood.

[17]  H. Kantarjian,et al.  Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. , 2011, Blood.

[18]  Dl Hoyert,et al.  National Vital Statistics Reports NCHS.pdf , 2012 .

[19]  C. Preudhomme,et al.  Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study. , 2011, Blood.

[20]  E. Arias.  United States life tables, 2007. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[21]  L. Dušek,et al.  Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 – a report from the population‐based CAMELIA Registry , 2011, European Journal of Haematology.

[22]  H. Kantarjian,et al.  Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. , 2011, Blood.

[23]  E. Jabbour,et al.  Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia , 2011, Leukemia.

[24]  H. Kantarjian,et al.  Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. , 2008, Blood.

[25]  E. Arias,et al.  United States life tables, 2006. , 2010, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[26]  E. Arias,et al.  United States life tables, 2005. , 2010, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[27]  Susan O'Brien,et al.  Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Susan O'Brien,et al.  Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Kantarjian,et al.  Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  H. Kantarjian,et al.  Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. , 2009, Blood.

[31]  E. Arias,et al.  United States life tables, 2004. , 2007, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[32]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[33]  Susan O'Brien,et al.  Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. , 2006, Blood.

[34]  E. Arias,et al.  United States life tables, 2005. , 2010, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[35]  F. Guilhot,et al.  Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia , 2005, Leukemia.

[36]  E. Arias,et al.  United States life tables, 2002. , 2004, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[37]  E. Arias.  United States Life Tables, 2001. , 2004, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[38]  Andrew K. Lee,et al.  Mortality after cure of testicular seminoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  H. Kantarjian,et al.  Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis , 2003, Cancer.

[40]  E. Arias,et al.  United States life tables, 2000. , 2002, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[41]  F. Ederer,et al.  The relative survival rate: a statistical methodology. , 1961, National Cancer Institute monograph.